Synergy Pharmaceuticals has revealed positive Phase IIa trial results for plecanatide, a new treatment for chronic constipation.

The double-blind, dose-escalation, randomised, placebo-controlled, cohort-design and multi-centre clinical trial evaluated the pharmacodynamic safety of the drug.

The findings showed that the patients who received plecanatide had improved bowel function, more frequent bowel movements and less abdominal discomfort.

Plecanatide also demonstrated an improved safety profile and no severe adverse events were observed.

The study enrolled 78 evaluable patients, who received a once-daily dose of placebo or plecanatide for 14 consecutive days at oral doses of 0.3mg, 1mg, 3mg or 9mg.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.